{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:07:05Z","timestamp":1791378425147,"version":"4.3.2"},"reference-count":50,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972366"],"award-info":[{"award-number":["81972366"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangdong Key Laboratory","award":["2017B030301015"],"award-info":[{"award-number":["2017B030301015"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,5,20]]},"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study developed a prognostic nomogram of Hodgkin lymphoma (HL) for purpose of discussing independent risk factors for HL patients with Surveillance, Epidemiology and End Results (SEER) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We collected data of HL patients from 2010 to 2015 from the SEER database and divided it into two cohorts: the training and the verification cohort. Then the univariate and the multivariate Cox regression analyses were conducted in the training, the verification as well as the total cohort, after which the intersection of variables with statistical significance was taken as independent risk factors to establish the nomogram. The predictive ability of the nomogram was validated by the Concordance Index. Additionally, the calibration curve and receiver operating characteristic curve were implemented to evaluate the accuracy and discrimination. Finally, we obtained 1-year, 3-year and 5-year survival rates of HL patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>10 912 patients were eligible for the study. We discovered that Derived American Joint Committee on Cancer (AJCC) Stage Group, lymphoma subtype, radiotherapy and chemotherapy were four independent risk factors affecting the prognosis of HL patients. The 1-year, 3-year and 5-year survival rates for high-risk patients were 85.4%, 79.9% and 76.0%, respectively. It was confirmed that patients with stage I or II had a better prognosis. Radiotherapy and chemotherapy had a positive impact on HL outcomes. However, patients with lymphocyte-depleted HL were of poor prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The nomogram we constructed could better predict the prognosis of patients with HL. Patients with HL had good long-term outcomes but novel therapies are still in need for fewer complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-055524","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T11:20:31Z","timestamp":1654600831000},"page":"e055524","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Nomogram model and risk score predicting overall survival and guiding clinical decision in patients with Hodgkin\u2019s lymphoma: an observational study using SEER population-based data"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct02927769","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02298283","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xiangping","family":"Liang","sequence":"first","affiliation":[{"name":"School of Laboratory Medicine, Hangzhou Medical College, Hangzhou, People's Republic of China"},{"name":"Department of Reproductive Medical Center, Guangdong Women and Children Hospital, Guangzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingtao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Computational Oncology Laboratory, Guangdong Medical University, Zhanjiang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zherui","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Laboratory and Biotechnology, Southern Medical University, Guangzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhen","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqi","family":"Li","sequence":"additional","affiliation":[{"name":"Computational Oncology Laboratory, Guangdong Medical University, Zhanjiang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyuan","family":"Zhong","sequence":"additional","affiliation":[{"name":"Computational Oncology Laboratory, Guangdong Medical University, Zhanjiang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqi","family":"Shao","sequence":"additional","affiliation":[{"name":"Computational Oncology Laboratory, Guangdong Medical University, Zhanjiang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Kong","sequence":"additional","affiliation":[{"name":"Computational Oncology Laboratory, Guangdong Medical University, Zhanjiang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[{"name":"Computational Oncology Laboratory, Guangdong Medical University, Zhanjiang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang","family":"Li","sequence":"additional","affiliation":[{"name":"Computational Oncology Laboratory, Guangdong Medical University, Zhanjiang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zesong","family":"Li","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Department of Urology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital (Shenzhen Institute of Translational Medicine), Shenzhen, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1737-3386","authenticated-orcid":false,"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine, Hangzhou Medical College, Hangzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"2025121510510520000_12.6.e055524.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21565"},{"key":"2025121510510520000_12.6.e055524.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"2025121510510520000_12.6.e055524.3","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/91.2.131"},{"key":"2025121510510520000_12.6.e055524.4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21438"},{"key":"2025121510510520000_12.6.e055524.5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.21647","article-title":"Incidence of death from unintentional injury among patients with cancer in the United States","volume":"3","author":"Yang","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025121510510520000_12.6.e055524.6","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.143.1.7063747"},{"key":"2025121510510520000_12.6.e055524.7","doi-asserted-by":"crossref","first-page":"796","DOI":"10.21037\/atm.2019.08.63","article-title":"In-depth mining of clinical data: the construction of clinical prediction model with R","volume":"7","author":"Zhou","year":"2019","journal-title":"Ann Transl Med"},{"key":"2025121510510520000_12.6.e055524.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.7418"},{"key":"2025121510510520000_12.6.e055524.9","doi-asserted-by":"crossref","first-page":"109811","DOI":"10.1016\/j.biopha.2020.109811","article-title":"Melatonin triggers autophagic cell death by regulating RORC in Hodgkin lymphoma","volume":"123","author":"Yan","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"2025121510510520000_12.6.e055524.10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025121510510520000_12.6.e055524.11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.radonc.2017.07.016","article-title":"Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: a propensity matched analysis of the surveillance, epidemiology, and end results database","volume":"124","author":"Bates","year":"2017","journal-title":"Radiother Oncol"},{"key":"2025121510510520000_12.6.e055524.12","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","article-title":"Classical Hodgkin lymphoma","volume":"398","author":"Brice","year":"2021","journal-title":"Lancet"},{"key":"2025121510510520000_12.6.e055524.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2005.04.014"},{"key":"2025121510510520000_12.6.e055524.14","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1080\/10428194.2019.1633636","article-title":"Prognostic factors and nomogram for survival prediction in patients with primary pulmonary lymphoma: a SEER population-based study","volume":"60","author":"Low","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2025121510510520000_12.6.e055524.15","first-page":"3035","article-title":"Effect of radiation therapy on survival in Hodgkin's lymphoma: a SEER data analysis","volume":"37","author":"Master","year":"2017","journal-title":"Anticancer Res"},{"key":"2025121510510520000_12.6.e055524.16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.16525","article-title":"First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study","volume":"190","author":"Rodday","year":"2020","journal-title":"Br J Haematol"},{"key":"2025121510510520000_12.6.e055524.17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25856"},{"key":"2025121510510520000_12.6.e055524.18","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN Guidelines\u00ae insights: B-cell lymphomas, version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2025121510510520000_12.6.e055524.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-772665"},{"key":"2025121510510520000_12.6.e055524.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.12.002"},{"key":"2025121510510520000_12.6.e055524.21","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography Response-Adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025121510510520000_12.6.e055524.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408648"},{"key":"2025121510510520000_12.6.e055524.23","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission Tomography-Guided treatment in early-stage favorable Hodgkin lymphoma: final results of the International, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025121510510520000_12.6.e055524.24","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0026"},{"key":"2025121510510520000_12.6.e055524.25","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.17.00175"},{"key":"2025121510510520000_12.6.e055524.26","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1016\/S2352-3026(21)00029-6","article-title":"Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, International phase 3 trial of the German Hodgkin Study Group (GHSG HD14)","volume":"8","author":"Gillessen","year":"2021","journal-title":"Lancet Haematol"},{"key":"2025121510510520000_12.6.e055524.27","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1016\/S2352-3026(18)30140-6","article-title":"Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials","volume":"5","author":"von Tresckow","year":"2018","journal-title":"Lancet Haematol"},{"key":"2025121510510520000_12.6.e055524.28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000719"},{"key":"2025121510510520000_12.6.e055524.29","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1080\/10428194.2020.1768388","article-title":"Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816","volume":"61","author":"Ha","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"2025121510510520000_12.6.e055524.30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with Escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025121510510520000_12.6.e055524.31","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(20)30357-4","article-title":"The role of PET in first-line treatment of Hodgkin lymphoma","volume":"8","author":"Trotman","year":"2021","journal-title":"Lancet Haematol"},{"key":"2025121510510520000_12.6.e055524.32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/humupd\/dmz041","article-title":"Do cancer therapies damage the uterus and compromise fertility?","volume":"26","author":"Griffiths","year":"2020","journal-title":"Hum Reprod Update"},{"key":"2025121510510520000_12.6.e055524.33","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/cac2.12111","article-title":"Abscopal effect of stereotactic radiotherapy combined with anti-PD-1\/PD-L1 immunotherapy: mechanisms, clinical efficacy, and issues","volume":"40","author":"Zhuang","year":"2020","journal-title":"Cancer Commun"},{"key":"2025121510510520000_12.6.e055524.34","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.2217\/fon-2019-0416","article-title":"Radiation-induced intestinal damage: latest molecular and clinical developments","volume":"15","author":"Lu","year":"2019","journal-title":"Future Oncol"},{"key":"2025121510510520000_12.6.e055524.35","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13419"},{"key":"2025121510510520000_12.6.e055524.36","first-page":"CD007941","article-title":"Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma","volume":"5","author":"Skoetz","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121510510520000_12.6.e055524.37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.beha.2012.01.006","article-title":"Image-guided needle biopsy for diagnosis and molecular biology in lymphomas","volume":"25","author":"de Kerviler","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"key":"2025121510510520000_12.6.e055524.38","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025121510510520000_12.6.e055524.39","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025121510510520000_12.6.e055524.40","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/14712598.2018.1499723","article-title":"Efficacy of antibody-drug conjugate brentuximab vedotin in treating Hodgkin's lymphoma","volume":"18","author":"Viviani","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"2025121510510520000_12.6.e055524.41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2435"},{"key":"2025121510510520000_12.6.e055524.42","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood"},{"key":"2025121510510520000_12.6.e055524.43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"2025121510510520000_12.6.e055524.44","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","article-title":"Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group","volume":"18","author":"Eichenauer","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025121510510520000_12.6.e055524.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811224"},{"key":"2025121510510520000_12.6.e055524.46","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29212","article-title":"Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031","volume":"68","author":"Milgrom","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"2025121510510520000_12.6.e055524.47","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bjh.17719","article-title":"Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping","volume":"195","author":"Alcoceba","year":"2021","journal-title":"Br J Haematol"},{"key":"2025121510510520000_12.6.e055524.48","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5644\/ama2006-124.329","article-title":"Classic Hodgkin Lymphoma - Old Disease, New Directions: An Update on Pathology, Molecular Features and Biological Prognostic Markers","volume":"50","author":"Perry","year":"2021","journal-title":"Acta Med Acad"},{"key":"2025121510510520000_12.6.e055524.49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143597","article-title":"The role of tumor-associated macrophages in hematologic malignancies","volume":"13","author":"Cencini","year":"2021","journal-title":"Cancers"},{"key":"2025121510510520000_12.6.e055524.50","first-page":"130","article-title":"Relationship of tumor-associated macrophage population detected by CD68 PG-M1, CD68 KP1, and CD163 with latent EBV infection and prognosis in classical Hodgkin lymphoma","volume":"37","author":"Mavili","year":"2021","journal-title":"Turk Patoloji Derg"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-055524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:51:18Z","timestamp":1765824678000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-055524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,7]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/bmjopen-2021-055524"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-055524","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}